Journal of Nephrology

, Volume 31, Issue 2, pp 197–208 | Cite as

ANCA-associated vasculitis with renal involvement

  • Valentina BindaEmail author
  • Gabriella Moroni
  • Piergiorgio Messa


Systemic vasculitis is a rare but severe group of diseases characterized by inflammation and necrosis of blood vessels. The size of the vessel affected varies among the different forms of vasculitis and there are three main subgroups: large, medium and small vessel vasculitis. Among small vessel vasculitis, the antineutrophil cytoplasmic antibody (ANCA)-associated forms are of particular importance. This subgroup includes: microscopic polyangiitis, granulomatosis with polyangiitis (Wegener’s), eosinophilic granulomatosis with polyangiitis (Churg–Strauss) and the form limited to the kidney. ANCA are serum autoantibodies directed against proteins present in the cytoplasmic granules of neutrophils and represent the serological markers of small vessel vasculitis. Renal involvement is present in the majority of patients with ANCA-associated vasculitis (AAV) and the consequences of a missed or delayed diagnosis of renal vasculitis are potentially life threatening. Patient survival and the risk of end-stage renal disease are closely associated with renal function at presentation. The gold standard for diagnosis remains renal biopsy. In 2010, a new histopathological classification based on the percent of normal glomeruli, cellular crescent or global sclerotic glomeruli was proposed. The aim of this classification was to predict the renal prognosis. Nowadays, remission can be achieved and maintained in most cases with a combination of high-dose steroid and immunosuppressive drugs. This therapy has to be continued for at least 24 months after a substantial remission has been obtained because early cessation of treatment is associated with an increased risk of relapse. For this reason, patients should be regularly monitored in order to promptly diagnose and treat a possible recurrence of AAV. This review will focus on kidney involvement in AAV with an overview of the clinical–pathological characteristics and therapeutic strategy for these conditions.


Vasculitis ANCA Pathology Therapy 



We would like to thank Andrea Centa and Marina Balderacchi for their secretarial assistance.

Compliance with ethical standards

Conflict of interest

We declare no conflicts of interest.

Ethical statement

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Jennette JC et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthr Rheum 37:187–192CrossRefGoogle Scholar
  2. 2.
    Jennette JC et al (2013) 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthr Rheum 65(1):1–11CrossRefGoogle Scholar
  3. 3.
    Rahmattulla C et al (2016) Genetic variants in ANCA-associated vasculitis: a meta-analysis. Ann Rheum 75(9):1687–92CrossRefGoogle Scholar
  4. 4.
    Maritati F et al (2016) Kidney involvement in medium- and large-vessel vasculitis. J Nephrol 29(4):495–505CrossRefPubMedGoogle Scholar
  5. 5.
    Watts RA et al (2015) Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant 30(Suppl 1):1422Google Scholar
  6. 6.
    Mahr A et al (2004) Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg–Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthr Rheum 51(1):92–9CrossRefGoogle Scholar
  7. 7.
    O’Donnell JL et al (2007) Wegener’s granulomatosis in New Zealand: evidence for a latitude-dependent incidence gradient. Intern Med J 37(4):242–246CrossRefPubMedGoogle Scholar
  8. 8.
    Andrews M et al (1990) Systemic vasculitis in the 1980s—is there an increasing incidence of Wegener’s granulomatosis and microscopic polyarteritis? J R Coll Physicians Lond 24(4):284–288PubMedGoogle Scholar
  9. 9.
    Knight A et al (2006) Increasing incidence of Wegener’s granulomatosis in Sweden, 1975–2001. J Rheumatol 33(10):2060–2063PubMedGoogle Scholar
  10. 10.
    Radice A et al (2013) Anti-neutrophil cytoplasmic autoantibodies: methodological aspects and clinical significance in systemic vasculitis. Autoimmun Rev 12(4):487–495CrossRefPubMedGoogle Scholar
  11. 11.
    Radice A et al (2000) Contribution of immunofluorescence to the identification and characterization of anti-neutrophil cytoplasmic autoantibodies. The role of different fixatives. Clin Exp Rheumatol 18(6):707–712PubMedGoogle Scholar
  12. 12.
    Taylor MV et al (2007) Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA). Clin Exp Immunol 150:42–48CrossRefGoogle Scholar
  13. 13.
    Kida I et al (2011) Antineutrophil cytoplasmic antibodies against myeloperoxidase, proteinase 3, elastase, cathepsin G and lactoferrin in Japanese patients with rheumatoid arthritis. Mod Rheumatol 21:43–50CrossRefPubMedGoogle Scholar
  14. 14.
    Khanna D et al (2003) Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis. J Rheumatol 30:1248–1252PubMedGoogle Scholar
  15. 15.
    Kain R et al (2008) Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 14(10):1088–1096CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kain R et al (2012) High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol 23(3):556–566CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Shah S et al (2016) A historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis. Clin Rheumatol 35:953–960CrossRefPubMedGoogle Scholar
  18. 18.
    Rowaiye OO et al (2015) The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis. Clin Kidney J 8(3):343–350CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Jennette JC, Falk RJ (2014) Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 10(8):463–473CrossRefPubMedGoogle Scholar
  20. 20.
    Xiao H et al (2015) Overview of the pathogenesis of ANCA-associated vasculitis. Kidney Dis 1(4):205–15CrossRefGoogle Scholar
  21. 21.
    Popa ER et al (2002) Staphylococcus aureus and Wegener’s granulomatosis. Arthr Res 4(2):77–79CrossRefGoogle Scholar
  22. 22.
    Csernok E et al (2010) Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis. Curr Opin Rheumatol 22(1):43–48CrossRefPubMedGoogle Scholar
  23. 23.
    Finkielman JD et al (2007) ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med 120(7):643.e9–643.14CrossRefGoogle Scholar
  24. 24.
    Cornec D et al (2016) ANCA-associated vasculitis—clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol 12(10):570–579CrossRefPubMedGoogle Scholar
  25. 25.
    Schirmer JH et al (2016) Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener’s) is a clinically distinct subset of ANCA-associated vasculitis: a retrospective analysis of 315 patients from a German Vasculitis Referral Center. Arthr Rheumatol 68(12):2953–2963CrossRefGoogle Scholar
  26. 26.
    Lyons PA et al (2012) Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 367:214–223CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Chung SA et al (2012) Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener’s) reveals shared susceptibility loci with rheumatoid arthritis. Arthr Rheum 64:3463–3471CrossRefGoogle Scholar
  28. 28.
    Xie G et al (2013) Association of granulomatosis with polyangiitis (Wegener’s) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthr Rheum 65:2457–2468CrossRefGoogle Scholar
  29. 29.
    Hilhorst M et al (2016) HLA-DPB1 as a risk factor for relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a cohort study. Arthr Rheumatol 68:1721–1730CrossRefGoogle Scholar
  30. 30.
    Jayne D (2009) The diagnosis of vasculitis. Best Pract Res Clin Rheumatol 23(3):445–453CrossRefPubMedGoogle Scholar
  31. 31.
    Sinico RA et al (2013) Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev 12(4):477–482CrossRefPubMedGoogle Scholar
  32. 32.
    Kallenberg CG (2014) The diagnosis and classification of microscopic polyangiitis. J Autoimmun 48–49:90–93CrossRefPubMedGoogle Scholar
  33. 33.
    Jennette JC, Olson JL, Schwartz MM, Silva FG (eds) (1998) Heptinstall’s pathology of the kidney, 5th edn. Lippincott-Raven publishers, Philadelphia, pp 625–656Google Scholar
  34. 34.
    Sinico RA, Meroni P (2013) The kaleidoscopic manifestations of systemic vasculitis. Autoimmun Rev 12(4):459–462CrossRefPubMedGoogle Scholar
  35. 35.
    Schilder AM (2010) Wegener’s granulomatosis vasculitis and granuloma. Autoimmun Rev 9(7):483–487CrossRefPubMedGoogle Scholar
  36. 36.
    Trimarchi M et al (2013) Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener’s). Autoimmun Rev 12(4):501–505CrossRefPubMedGoogle Scholar
  37. 37.
    Pagnoux C (2016) Updates in ANCA-associated vasculitis. Eur J Rheumatol 3(3):122–133CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Groh M et al (2015) Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 26:545–553CrossRefPubMedGoogle Scholar
  39. 39.
    Sinico RA et al (2005) Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg–Strauss syndrome. Arthr Rheum 52:2926–2935CrossRefGoogle Scholar
  40. 40.
    Sable-Fourtassou R et al (2005) Antineutrophil cytoplasmic antibodies and the Churg–Strauss syndrome. Ann Intern Med 143:632–638CrossRefPubMedGoogle Scholar
  41. 41.
    Berden AE et al (2010) Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21(10):1628–1636CrossRefPubMedGoogle Scholar
  42. 42.
    Chang DY et al (2012) Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. Nephrol Dial Transplant 27:2343–2349CrossRefPubMedGoogle Scholar
  43. 43.
    Muso E et al (2013) Evaluation of the newly proposed simplified histological classification in Japanese cohorts of myeloperoxidase-anti-neutrophil cytoplasmic antibody associated glomerulonephritis in comparison with other Asian and European cohorts. Clin Exp Nephrol 17(5):659–662CrossRefPubMedGoogle Scholar
  44. 44.
    Moroni G et al (2015) Predictors of renal survival in ANCA-associated vasculitis. Validation of a histopathological classification schema and review of the literature. Clin Exp Rheumatol 33(2 Suppl 89):S56–S63Google Scholar
  45. 45.
    Tanna A et al (2015) Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrol Dial Transplant 30:1185–1192CrossRefPubMedGoogle Scholar
  46. 46.
    Hilhorst M et al (2013) Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant 28:373–379CrossRefPubMedGoogle Scholar
  47. 47.
    Quintana LF et al (2014) ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. Nephrol Dial Transplant 29:1764–1769CrossRefPubMedGoogle Scholar
  48. 48.
    Ford SL et al (2014) Histopathologic and clinical predictors of kidney outcomes in ANCA-associated vasculitis. Am J Kidney Dis 63:227–235CrossRefPubMedGoogle Scholar
  49. 49.
    Bjorneklett R et al (2016) Prognostic value of histologic classification of ANCA-associated glomerulonephritis. Clin J Am Soc Nephrol 11(12):2159–2167CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Diaz-Crespo F et al (2016) The predictive value of kidney biopsy in renal vasculitis: a multicenter cohort study. Hum Pathol 52:119–127CrossRefPubMedGoogle Scholar
  51. 51.
    Yates M et al (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594CrossRefPubMedGoogle Scholar
  52. 52.
    Novack SN, Pearson CM (1971) Cyclophosphamide therapy in Wegener’s granulomatosis. N Engl J Med 284:938–942CrossRefPubMedGoogle Scholar
  53. 53.
    De Groot K et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150:670–680CrossRefPubMedGoogle Scholar
  54. 54.
    Guillevin L et al (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthr Rheum 40:2187–2198CrossRefGoogle Scholar
  55. 55.
    Harper L et al (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71:955–960CrossRefPubMedGoogle Scholar
  56. 56.
    Cohen P et al (2007) Churg–Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthr Rheum 57:686–693CrossRefGoogle Scholar
  57. 57.
    Jones RB et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211–220CrossRefPubMedGoogle Scholar
  58. 58.
    Stone JH et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Mohammad AJ et al (2016) Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Ann Rheum Dis 75:396–401CrossRefPubMedGoogle Scholar
  60. 60.
    Jayne DR et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. European Vasculitis Study Group. J Am Soc Nephrol 18(7):2180–2188CrossRefPubMedGoogle Scholar
  61. 61.
    Walsh M et al (2013) Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 14:73CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Jayne D et al (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36–44CrossRefPubMedGoogle Scholar
  63. 63.
    Guillevin L et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771–1780CrossRefPubMedGoogle Scholar
  64. 64.
    Pagnoux C et al (2008) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359:2790–2803CrossRefPubMedGoogle Scholar
  65. 65.
    Hiemstra TF et al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304:2381–2388CrossRefPubMedGoogle Scholar
  66. 66.
    Flossmann O et al (2010) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70:488–494CrossRefPubMedGoogle Scholar
  67. 67.
    Westman K, Flossmann O, Gregorini G (2015) The long-term outcomes of systemic vasculitis. Nephrol Dial Transplant 30(Suppl 1):60–66Google Scholar
  68. 68.
    Chang DY et al (2012) Association of HLA genes with clinical outcomes of ANCA-associated vasculitis. Clin J Am Soc Nephrol 7:1293–1299CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Slot MC et al (2003) Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 63:670–677CrossRefPubMedGoogle Scholar
  70. 70.
    Hogan SL et al (2005) Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143:621–631CrossRefPubMedGoogle Scholar
  71. 71.
    Moroni G, Ponticelli C (2014) Rapidly progressive crescentic glomerulonephritis: early treatment is a must. Autoimmun Rev 13:723–729CrossRefPubMedGoogle Scholar

Copyright information

© Italian Society of Nephrology 2017

Authors and Affiliations

  • Valentina Binda
    • 1
    Email author
  • Gabriella Moroni
    • 1
  • Piergiorgio Messa
    • 1
    • 2
  1. 1.Divisione di Nefrologia e Dialisi-Padiglione CroffFondazione Ca’ Granda IRCCS Ospedale Maggiore Policlinico di MilanoMilanItaly
  2. 2.Area Omogenea Nefro-Urologica e Trapianto di Rene, Fondazione Ca’ Granda IRCCS Ospedale Maggiore Policlinico di MilanoUniversità degli studi di MilanoMilanItaly

Personalised recommendations